I-Mab(I-Mab) is a biopharmaceutical company. It develops transformational medicines for therapeutic areas of immuno-oncology and autoimmune diseases. Its pipeline product portfolio comprises TJ202, a CD38 antibody for treating multiple myeloma; TJ101, a recombinant human growth hormone (rhGH) used in pediatric patients with growth hormone deficiency; TJ301, an IL-6 inhibitor for ulcerative colitis; enoblituzumab, a B7-H3 antibody against tumors; and TJ107, an oncology care agent to treat cancer treatment-related lymphopenia. I-Mab utilizes various molecular engineering platforms to develop drug molecules with defined biological properties. The company collaborates with biotechnology companies, CROs, and CMOs to advance the clinical development of its pipeline assets and out-licensing opportunities. It operates in China, Hong Kong and the US. I-Mab is headquartered in Shanghai, China.

Gain a 360-degree view of I-Mab and make more informed decisions for your business Gain a 360-degree view of I-Mab and make more informed decisions for your business Contact Us
Headquarters China

Address Willow House, Floor 4, Shanghai, 200124


Telephone 86 21 60578000

No of Employees 318

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange IMAB (NASD)

EPS XYZ

Market Cap* $153.7M

Net Profit Margin (2021) XYZ -8,775.7%

   

   

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Contact Us

I-Mab premium industry data and analytics

100+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for I-Mab’s relevant decision makers and contact details.

70+

Catalyst Calendar

Proactively evaluate I-Mab’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

50+

Pipeline Drugs

Identify which of I-Mab’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Clinical Trials

Determine I-Mab go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

5

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Products and Services

Products
TJ202 (Felzartamab): Multiple Myeloma
TJ101 (Eftansomatropin): Pediatric Growth Hormone Deficiency
TJ271 (Enoblituzumab): Non-Small Cell Lung Cancer
XYZ
XYZ
XYZ
Understand I-Mab portfolio and identify potential areas for collaboration Understand I-Mab portfolio and identify potential areas for collaboration Contact Us

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Contracts/Agreements In February, the company signed agreements to divest its assets and business operations in China.
2022 Others In August, the company announced to concentrate its drug development efforts on five key candidates.
2022 Contracts/Agreements In June, the company entered into a strategic collaboration with Ferring Pharmaceuticals to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Contact Us
Image for loader

Competitor Comparison

Key Parameters I-Mab Akeso Inc CStone Pharmaceuticals Co Ltd JW Cayman Therapeutics Co Ltd CARsgen Therapeutics Ltd
Headquarters China China China China China
City Shanghai Zhongshan Shanghai Shanghai Shanghai
State/Province Shanghai Guangdong Shanghai Shanghai Shanghai
No. of Employees 318 2,520 199 490 525
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Contact Us
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Contact Us
Executives
Name Position Board Since Age
Jingwu Zhang Zang Chairman Executive Board 2021 67
Richard Yeh Chief Financial Officer - Interim; Director; Chief Operating Officer Executive Board 2022 54
Andrew Zhu President; Chief Executive Officer - Acting; Director Executive Board 2021 62
Raj Kannan Chief Executive Officer Senior Management 2023 -
Richard Cheng Li Chief Legal Officer Senior Management 2021 38
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into I-Mab key executives to enhance your sales strategy Gain insight into I-Mab key executives to enhance your sales strategy Contact Us
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward